Revalesio To Unveil Key Findings from RNS60 Trial for Stroke Treatment at SNIS Conference

Revalesio, a progressive pharmaceutical firm focused on innovative treatments for neurological disorders, is set to make significant presentations at the upcoming Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting in Nashville, Tennessee from July 14-18, 2025. The company will share two pivotal studies on its investigational drug, RNS60, aimed at addressing acute ischemic stroke (AIS). These findings are critical for advancing understanding and treatment options in this often-debilitating condition.

The presentations are scheduled for July 17, 2025, and will delve into the design of the upcoming Phase 3 trial named RESTORE, as well as new insights uncovered in the post hoc analysis of the previously conducted Phase 2 RESCUE trial. The first presentation, titled "RESTORE: A Phase 3 Study Evaluating Efficacy and Safety of RNS60 as an Adjunct Cytoprotective Treatment in Patients with Acute Ischemic Stroke Undergoing Endovascular Thrombectomy," will take place from 12:20-12:25 PM Central Time. The second session will focus on the post hoc analysis, showcasing improvements in various efficacy endpoints for participants who were enrolled within 12 hours of symptom onset. This will be presented from 12:40-12:45 PM CT.

RNS60 is designed to be a treatment adjunct during the endovascular thrombectomy process. Its primary purpose is to minimize infarct growth during the acute phase of injury after a stroke, thereby enhancing the chances for survivors to maintain their functional independence. Greg Archambeau, the President of Revalesio and co-inventor of RNS60, stated, "The unique design of our Phase 2 RESCUE trial centered on demonstrating RNS60's capability to decrease the growth of the brain tissue loss post-thrombectomy. We observed that patients treated with the high-dose of RNS60 experienced significantly less brain volume loss compared to those receiving a placebo. Notably, this reduction in brain tissue loss correlates strongly with improved patient outcomes."

The RESCUE trial itself was a comprehensive, multi-center, double-blinded, and placebo-controlled study involving eighty-two AIS patients eligible for endovascular thrombectomy. In this trial, participants received various dosages of RNS60, either low (0.5 mL/kg/h) or high (1.0 mL/kg/h), or a placebo, starting just before the completion of the thrombectomy and continuing for a 48-hour period. The primary endpoints assessed were safety and mortality rates, while secondary endpoints evaluated disability using the modified Rankin Scale (mRS), MRI changes at 48 hours, and additional metrics including Barthel Index, NIH Stroke Scale, and EQ-5D-5L for quality of life measurement.

RNS60 stands at the forefront of clinical research as a potentially disease-modifying therapy, aimed not only at acute treatment but also leveraging its protective effects on neurons and other critical brain cells. Preclinical studies indicate that RNS60 plays a pivotal role in activating essential cellular pathways to enhance mitochondrial health and reduce inflammation—two crucial factors in the aftermath of a stroke.

Revalesio’s mission is to innovate treatments for both acute and chronic neurological conditions. With its flagship program targeting ischemic stroke, the company also maintains avenues of research aimed at other debilitating neurological disorders, including amyotrophic lateral sclerosis (ALS). Their groundbreaking approach, derived from principles of physics, seeks to address the core mechanisms required for optimal cellular functions. By doing so, Revalesio aims to slow disease progression and, ultimately, enhance the quality of life for those affected.

As the SNIS Annual Meeting approaches, interest in the effectiveness of RNS60 continues to build, with many stakeholders in the medical community eager to explore its potential impact on treatment protocols for acute ischemic stroke. To learn more about Revalesio and their pioneering efforts in neurological treatment, visit their official website at revalesio.com and follow their engagements on LinkedIn.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.